Teiji Kuzuya

20PUBLICATIONS
45CO-AUTHORS
Predictive and prognostic markersTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Pacific Peoples diet and nutritionElectrical and electromagnetic methods in geophysics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jul 28, 2026
Clinical Utility and Genomic Landscape of Comprehensive Genomic Profiling in Biliary Tract Tumors: A Single-Center Real-World Study.

|Jul 15, 2026
Efficacy of Second-Line Lenvatinib After Atezolizumab-Bevacizumab and Durvalumab-Tremelimumab in Unresectable Hepatocellular Carcinoma: Association with Prior Immunotherapy Response.

|Jan 28, 2026
The Central Role of Liver Function at Treatment Initiation and Its Preservation at Progression for Post-Progression Survival After Atezolizumab Plus Bevacizumab in Advanced Hepatocellular Carcinoma.

Mizuki Ariga, Teiji Kuzuya, Hisanori Muto

|Dec 30, 2025
Biomarker-Based Responder Selection and Early Prediction of Treatment Response in Hepatocellular Carcinoma: Dynamic Changes in Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin During Atezolizumab Plus Bevacizumab Therapy.

Teiji Kuzuya, Hisanori Muto, Yoshihiko Tachi

|Nov 03, 2025
Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT.

Kazuomi Ueshima, Kaoru Tsuchiya, Tatsuya Yamashita

|Aug 28, 2025
Rechallenge of Atezolizumab Plus Bevacizumab Therapy in Patients With Unresectable Hepatocellular Carcinoma.

Yuichiro Suzuki, Teiji Kuzuya, Leona Osawa

Pageof 4

Frequent Collaborators

10 joint publications

Yoshiki Hirooka

8 joint publications

Kazunori Nakaoka

8 joint publications

Kohei Funasaka

4 joint publications

Senju Hashimoto